|Bid||40.88 x 0|
|Ask||41.00 x 0|
|Day's Range||40.14 - 41.50|
|52 Week Range||33.46 - 54.10|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.12|
Basel, Switzerland, September 30, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that a post-hoc analysis of efficacy data from a previously completed phase 1/2.
Basel, Switzerland, August 27, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the completion of patient enrolment in its phase 1 study with the oral formulation.
Revenue from Cresemba® and Zevtera® increased by 91% to CHF 53 millionOperating result improved by 35%Expansion of derazantinib clinical program into urothelial cancer with.
Basel, Switzerland, August 13, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 FIDES-02 study with the pan-fibroblast growth.
Ceftobiprole met primary and secondary efficacy endpoints in the treatment of ABSSSICeftobiprole was well tolerated Basel, Switzerland, August 06, 2019 – Basilea.
Basel, Switzerland, July 01, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the first patient was enrolled in a newly opened cohort in the ongoing FIDES-01.
Basel, Switzerland, June 3, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today the phase 1 data from an ongoing study with the oral formulation of its novel tumor.
Basel, Switzerland, May 02, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Avir Pharma Inc. (“Avir Pharma”) has launched the antifungal Cresemba®.
SAN DIEGO, April 24, 2019 /PRNewswire/ -- Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes. Under the terms of the agreement, Basilea will make an upfront payment to Forge to access their BLACKSMITH platform for two targets.
Basel, Switzerland, April 12, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that a broad range of posters and presentations on the antifungal isavuconazole.
Basilea Pharmaceutica Ltd. (BSLN.SW) reported that shareholders approved all proposals of the Board of Directors at today’s Annual General Meeting (AGM) for the financial year 2018. The shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2018, and approved the discharge of the members of Basilea’s Board of Directors and Management Committee.
Total revenue increased 31% to CHF 133 million Revenue from Cresemba® and Zevtera® increased 56% to CHF 82 million Positive derazantinib phase 2 interim results and.
Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that the European sales of the antifungal Cresemba® (isavuconazole) by Pfizer exceeded the threshold triggering the first sales milestone payment to Basilea of USD 5 million. Basilea is entitled to receive sales milestone payments if Pfizer's cumulative Cresemba sales exceed certain thresholds. Pfizer is currently commercializing Cresemba in key European countries, including France, Germany, Italy, Spain and the U.K.
Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that the Board of Directors has appointed Adesh Kaul, currently Chief Corporate Development Officer and member of the Management Committee, as the new Chief Financial Officer (CFO) as of April 10, 2019. David Veitch, CEO of Basilea, said: "In Adesh Kaul we have an excellent CFO.
Basel, Switzerland, January 24, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of Basilea`s derazantinib ...
21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing.
Total revenue is expected to increase by 31% over 2017 to approx. CHF 133 million (FYR 2017: CHF 101.5 million), with contributions of approx. CHF 82 million (FYR 2017: CHF 52.5 million, + 56%) from Basilea`s two marketed products, the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole). Basilea had guided for total revenue of CHF 120-130 million and contributions from Cresemba and Zevtera of CHF 75-85 million for the financial year 2018.
Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that David Veitch, Chief Executive Officer of Basilea, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019 at 8:30 a.m. Pacific Standard Time / 5:30 p.m. Central European Time at the Westin St. Francis Hotel, San Francisco, CA. David Veitch will describe both the progress made during 2018 and the priorities for 2019 to deliver on the key elements of Basilea's strategy for continued value creation. The company is focused on continuously increasing revenues from its commercialized products, the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole), in addition to advancing and expanding its oncology and anti-infectives R&D pipeline.